Last reviewed · How we verify

ephedrine and phenylephrine

University Hospital, Clermont-Ferrand · FDA-approved active Small molecule

ephedrine and phenylephrine is a Sympathomimetic amine / Adrenergic agonist Small molecule drug developed by University Hospital, Clermont-Ferrand. It is currently FDA-approved for Hypotension (acute management), Nasal congestion and upper airway obstruction, Anaphylaxis (adjunctive).

Ephedrine and phenylephrine are sympathomimetic agents that stimulate alpha and beta adrenergic receptors to increase blood pressure and improve nasal/airway congestion.

Ephedrine and phenylephrine are sympathomimetic agents that stimulate alpha and beta adrenergic receptors to increase blood pressure and improve nasal/airway congestion. Used for Hypotension (acute management), Nasal congestion and upper airway obstruction, Anaphylaxis (adjunctive).

At a glance

Generic nameephedrine and phenylephrine
SponsorUniversity Hospital, Clermont-Ferrand
Drug classSympathomimetic amine / Adrenergic agonist
TargetAlpha-1 adrenergic receptor, beta-1 adrenergic receptor, beta-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaCardiovascular / Respiratory
PhaseFDA-approved

Mechanism of action

Ephedrine acts as a mixed alpha and beta-adrenergic agonist, increasing heart rate, cardiac output, and peripheral vasoconstriction to elevate blood pressure. Phenylephrine is a selective alpha-1 adrenergic agonist that causes vasoconstriction and increases systemic vascular resistance. Together, this combination provides both direct sympathomimetic effects and indirect norepinephrine release, making it useful for hypotension and decongestant purposes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ephedrine and phenylephrine

What is ephedrine and phenylephrine?

ephedrine and phenylephrine is a Sympathomimetic amine / Adrenergic agonist drug developed by University Hospital, Clermont-Ferrand, indicated for Hypotension (acute management), Nasal congestion and upper airway obstruction, Anaphylaxis (adjunctive).

How does ephedrine and phenylephrine work?

Ephedrine and phenylephrine are sympathomimetic agents that stimulate alpha and beta adrenergic receptors to increase blood pressure and improve nasal/airway congestion.

What is ephedrine and phenylephrine used for?

ephedrine and phenylephrine is indicated for Hypotension (acute management), Nasal congestion and upper airway obstruction, Anaphylaxis (adjunctive).

Who makes ephedrine and phenylephrine?

ephedrine and phenylephrine is developed and marketed by University Hospital, Clermont-Ferrand (see full University Hospital, Clermont-Ferrand pipeline at /company/university-hospital-clermont-ferrand).

What drug class is ephedrine and phenylephrine in?

ephedrine and phenylephrine belongs to the Sympathomimetic amine / Adrenergic agonist class. See all Sympathomimetic amine / Adrenergic agonist drugs at /class/sympathomimetic-amine-adrenergic-agonist.

What development phase is ephedrine and phenylephrine in?

ephedrine and phenylephrine is FDA-approved (marketed).

What are the side effects of ephedrine and phenylephrine?

Common side effects of ephedrine and phenylephrine include Tachycardia, Tremor, Anxiety, Insomnia, Headache, Hypertension.

What does ephedrine and phenylephrine target?

ephedrine and phenylephrine targets Alpha-1 adrenergic receptor, beta-1 adrenergic receptor, beta-2 adrenergic receptor and is a Sympathomimetic amine / Adrenergic agonist.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing